Identification of genetic mechanisms causing cancer therapy resistance using massive parallel sequencing
- Prosjektnummer
- 911872
- Ansvarlig person
- Per Eystein Lønning
- Institusjon
- Helse Bergen HF
- Prosjektkategori
- Åpen prosjektstøtte
- Helsekategori
- Cancer
- Forskningsaktivitet
- 5. Treatment Developement
DNA methylation signature (SAM40) identifies subgroups of the Luminal A breast cancer samples with distinct survival.
Oncotarget 2017 Jan 03;8(1):1074-1082.
PMID: 27911866
MDM2 promoter polymorphism del1518 (rs3730485) and its impact on endometrial and ovarian cancer risk.
BMC Cancer 2017 02 03;17(1):97. Epub 2017 feb 3
PMID: 28158999
High PTEN gene expression is a negative prognostic marker in human primary breast cancers with preserved p53 function.
Breast Cancer Res Treat 2017 May;163(1):177-190. Epub 2017 feb 17
PMID: 28213783
Impact of the MDM2 splice-variants MDM2-A, MDM2-B and MDM2-C on cytotoxic stress response in breast cancer cells.
BMC Cell Biol 2017 Apr 17;18(1):17. Epub 2017 apr 17
PMID: 28415963
Long-Term Follow-Up of the Intergroup Exemestane Study.
J Clin Oncol 2017 Aug 01;35(22):2507-2514. Epub 2017 mai 3
PMID: 28467729
Activation of Akt characterizes estrogen receptor positive human breast cancers which respond to anthracyclines.
Oncotarget 2017 Jun 20;8(25):41227-41241.
PMID: 28476032
Effects of concomitant inactivation of p53 and pRb on response to doxorubicin treatment in breast cancer cell lines.
Cell Death Discov 2017;3():17026. Epub 2017 mai 22
PMID: 28580174
Concerns About Methodology of a Trial Investigating Vaginal Health During Aromatase Inhibitor Therapy for Breast Cancer.
JAMA Oncol 2017 Aug 01;3(8):1140.
PMID: 28727878
Genomic Evolution of Breast Cancer Metastasis and Relapse.
Cancer Cell 2017 Aug 14;32(2):169-184.e7.
PMID: 28810143
Comment on "Towards a personalized approach to aromatase inhibitor therapy: a digital microfluidic platform for rapid analysis of estradiol in core-needle-biopsies" by S. Abdulwahab, A. H. C. Ng, M. D. Chamberlain, H. Ahmado, L.-A. Behan, H. Gomaa, R. F. Casper and A. R. Wheeler, Lab Chip, 2017, 17, 1594.
Lab Chip 2017 Sep 12;17(18):3186-3187.
PMID: 28816306
The Functional Roles of the MDM2 Splice Variants P2-MDM2-10 and MDM2-∆5 in Breast Cancer Cells.
Transl Oncol 2017 Oct;10(5):806-817. Epub 2017 aug 29
PMID: 28844019
APOBEC3A/B deletion polymorphism and cancer risk.
Carcinogenesis 2018 02 09;39(2):118-124.
PMID: 29140415
Evaluation of applying IHC4 as a prognostic model in the translational study of Intergroup Exemestane Study (IES): PathIES.
Breast Cancer Res Treat 2017 Nov 24. Epub 2017 nov 24
PMID: 29177605
Heterogeneous perivascular cell coverage affects breast cancer metastasis and response to chemotherapy.
JCI Insight 2016 Dec 22;1(21):e90733. Epub 2016 des 22
PMID: 28018977
Prevalence of the CHEK2 R95* germline mutation.
Hered Cancer Clin Pract 2016;14():19. Epub 2016 sep 27
PMID: 27708748
MDM2 promoter SNP55 (rs2870820) affects risk of colon cancer but not breast-, lung-, or prostate cancer.
Sci Rep 2016 Sep 14;6():33153. Epub 2016 sep 14
PMID: 27624283
Intra-patient Inter-metastatic Genetic Heterogeneity in Colorectal Cancer as a Key Determinant of Survival after Curative Liver Resection.
PLoS Genet 2016 Jul;12(7):e1006225. Epub 2016 jul 29
PMID: 27472274
Associations between the MDM2 promoter P1 polymorphism del1518 (rs3730485) and incidence of cancer of the breast, lung, colon and prostate.
Oncotarget 2016 May 10;7(19):28637-46.
PMID: 27081698
Impact of KRAS, BRAF, PIK3CA, TP53 status and intraindividual mutation heterogeneity on outcome after liver resection for colorectal cancer metastases.
Int J Cancer 2016 Aug 01;139(3):647-56. Epub 2016 apr 4
PMID: 26991344
Novel Mad2-targeting miR-493-3p controls mitotic fidelity and cancer cells' sensitivity to paclitaxel.
Oncotarget 2016 Mar 15;7(11):12267-85.
PMID: 26943585
The MDM4 SNP34091 (rs4245739) C-allele is associated with increased risk of ovarian-but not endometrial cancer.
Tumour Biol 2016 Aug;37(8):10697-702. Epub 2016 feb 11
PMID: 26867771
Incomplete Estrogen Suppression With Gonadotropin-Releasing Hormone Agonists May Reduce Clinical Efficacy in Premenopausal Women With Early Breast Cancer.
J Clin Oncol 2016 May 10;34(14):1580-3. Epub 2016 jan 4
PMID: 26729430
DNA methylation subgroups in melanoma are associated with proliferative and immunological processes.
BMC Med Genomics 2015;8():73. Epub 2015 nov 6
PMID: 26545983
MDM4 SNP34091 (rs4245739) and its effect on breast-, colon-, lung-, and prostate cancer risk.
Cancer Med 2015 Dec;4(12):1901-7. Epub 2015 okt 16
PMID: 26471763
Estrogens Correlate with PELP1 Expression in ER Positive Breast Cancer.
PLoS One 2015;10(8):e0134351. Epub 2015 aug 6
PMID: 26247365
Subclonal diversification of primary breast cancer revealed by multiregion sequencing.
Nat Med 2015 Jul;21(7):751-9. Epub 2015 jun 22
PMID: 26099045
Concomitant inactivation of the p53- and pRB- functional pathways predicts resistance to DNA damaging drugs in breast cancer in vivo.
Mol Oncol 2015 Oct;9(8):1553-64. Epub 2015 mai 8
PMID: 26004085
Prognostic and predictive value of ERß1 and ERß2 in the Intergroup Exemestane Study (IES)-first results from PathIES†.
Ann Oncol 2015 Sep;26(9):1890-7. Epub 2015 mai 22
PMID: 26002610
Normal breast tissue estrogen levels.
Maturitas 2015 Jun;81(2):327. Epub 2015 mar 16
PMID: 25864130
Genome-Wide DNA Methylation Analysis in Melanoma Reveals the Importance of CpG Methylation in MITF Regulation.
J Invest Dermatol 2015 Jul;135(7):1820-8. Epub 2015 feb 23
PMID: 25705847
Influence of MDM2 SNP309 and SNP285 status on the risk of cancer in the breast, prostate, lung and colon.
Int J Cancer 2015 Jul 1;137(1):96-103. Epub 2014 des 10
PMID: 25431177
Performance comparison of three BRAF V600E detection methods in malignant melanoma and colorectal cancer specimens.
Tumour Biol 2015 Feb;36(2):1003-13. Epub 2014 okt 16
PMID: 25318602
Relationship of body mass index with aromatisation and plasma and tissue oestrogen levels in postmenopausal breast cancer patients treated with aromatase inhibitors.
Eur J Cancer 2014 Apr;50(6):1055-64. Epub 2014 feb 4
PMID: 24507547
Effects of SNP variants in the 17ß-HSD2 and 17ß-HSD7 genes and 17ß-HSD7 copy number on gene transcript and estradiol levels in breast cancer tissue.
J Steroid Biochem Mol Biol 2014 Sep;143():192-8. Epub 2014 feb 18
PMID: 24560990
The emergence of targeted drugs in breast cancer to prevent resistance to endocrine treatment and chemotherapy.
Expert Opin Pharmacother 2014 Apr;15(5):681-700. Epub 2014 feb 28
PMID: 24579888
Interpreting plasma estrogen levels in breast cancer: caution needed.
J Clin Oncol 2014 May 10;32(14):1396-400. Epub 2014 apr 14
PMID: 24733806
MDM2 SNP309 and risk of cervical cancer.
Tumour Biol 2014 Jul;35(7):6185-6. Epub 2014 apr 17
PMID: 24740562
TP53 status predicts long-term survival in locally advanced breast cancer after primary chemotherapy.
Acta Oncol 2014 Oct;53(10):1347-55. Epub 2014 jun 9
PMID: 24909504
Estradiol measurement in translational studies of breast cancer.
Steroids 2015 Jul;99(Pt A):26-31. Epub 2014 aug 24
PMID: 25159101
DNA methylation status of key cell-cycle regulators such as CDKNA2/p16 and CCNA1 correlates with treatment response to doxorubicin and 5-fluorouracil in locally advanced breast tumors.
Clin Cancer Res 2014 Dec 15;20(24):6357-66. Epub 2014 okt 7
PMID: 25294903
The multitude of molecular analyses in cancer: the opening of Pandora's box.
Genome Biol 2014 Sep 3;15(9):447. Epub 2014 sep 3
PMID: 25316146
Population distribution and ancestry of the cancer protective MDM2 SNP285 (rs117039649).
Oncotarget 2014 Sep 30;5(18):8223-34.
PMID: 25327560
Mobile DNA in cancer. Extensive transduction of nonrepetitive DNA mediated by L1 retrotransposition in cancer genomes.
Science 2014 Aug 1;345(6196):1251343.
PMID: 25082706
Association of a germline copy number polymorphism of APOBEC3A and APOBEC3B with burden of putative APOBEC-dependent mutations in breast cancer.
Nat Genet 2014 May;46(5):487-91. Epub 2014 apr 13
PMID: 24728294
Genetic heterogeneity in liver metastases from colorectal cancer
- Disputert:
- april 2016
- Hovedveileder:
- Per Eystein Lønning
- Einar Elvbakken Birkeland Ph.d.-kandidat
- Stian Knappskog Leder av forskningsgruppe
- Hans Petter Eikesdal Leder av forskningsgruppe
- Synnøve Yndestad Ph.d.-kandidat
- Per Eystein Lønning Prosjektleder
- Anne Hege Straume Prosjektdeltaker
- Elisabet Ognedal Berge Prosjektdeltaker
- Deepak Poduval Ph.d.-kandidat
eRapport er utarbeidet av Sølvi Lerfald og Reidar Thorstensen, Regionalt kompetansesenter for klinisk forskning, Helse Vest RHF, og videreutvikles av de fire RHF-ene i fellesskap, med støtte fra Helse Vest IKT
Alle henvendelser rettes til Faglig rapportering, Helse Vest